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Background: Currently, endovascular treatment is indicated to treat femoropopliteal lesions ≤15 cm. However, the
Achilles’ heel of femoropopliteal endovascular repair remains restenosis. Paclitaxel eluting stents have shown promising
results to prevent restenosis in femoropopliteal lesions compared to percutaneous transluminal angioplasty. A recently
released prospective registry using a newer generation of self-expandable nitinol stents (Misago®; Terumo Corp., Tokyo,
Japan) supports primary bare metal stenting as a first-line treatment for femoropopliteal lesions. To date, no studies
have been designed to compare bare metal stents to paclitaxel eluting stents for the treatment of femoropoliteal
lesions. The BATTLE trial was designed to compare paclitaxel eluting stents (Zilver® PTX®) and a last generation
bare self-expandable nitinol stents (Misago® RX, Terumo Corp., Tokyo, Japan) in the treatment of intermediate
length femoropopliteal lesions (≤14 cm).
Methods/Design: A prospective, randomized (1:1), controlled, multicentric and international study has been designed.
One hundred and eighty-six patients fulfilling the inclusion criteria will be randomized to one of the two assessments
of endovascular repair to treat de novo femoropopliteal lesions ≤14 cm in symptomatic patients (Rutherford 2 to 5):
bare stent group and paclitaxel eluting stent group. The primary endpoint is freedom from in-stent restenosis at 1 year
defined by a peak systolic velocity index >2.4 (restenosis of >50%) at the target lesion and assessed by duplex scan.
Our main objective is to demonstrate the clinical superiority of primary stenting using Zilver® PTX® stent system versus
bare metal self-expandable stenting in the treatment of femoropopliteal lesions in patients with symptomatic
peripheral arterial disease.
Discussion: This is the first randomized and controlled study to compare the efficacy of bare metal stents and
paclitaxel eluting stents for the treatment of femoropopliteal lesions. It may clarify the indication of stent choice
for femoropopliteal lesions of intermediate length.
Trial registration: Clinicaltrials.gov identifier: NCT02004951. 3 December 2013.
Keywords: Superficial femoral artery, Bare metal stent, Drug eluting stent, Paclitaxel* Correspondence: yann.goueffic@chu-nantes.fr
1CHU Nantes, l’institut du thorax, service de chirurgie vasculaire, Nantes
F-44000, France
2INSERM, U957, Nantes F-44000, France
Full list of author information is available at the end of the article
© 2014 Gouëffic et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Gouëffic et al. Trials 2014, 15:423 Page 2 of 9
http://www.trialsjournal.com/content/15/1/423Background
In cases of atheromatous lesions of the femoropopliteal
segment, open or endovascular procedures could be pro-
posed to revascularize this segment. Over the past years,
endovascular procedures have become an important part
of treatment in patients with peripheral arterial disease
[1]. Indications for endovascular repair of femoropopli-
teal lesions have been considerably enlarged as shown in
the Trans-Atlantic Inter-Society Consensus Document
on Management of Peripheral Arterial Disease (TASC)
[1]. Enlargement of endovascular therapy indication is
based on patient choice for a less invasive technique and
evidence-based medicine. Consequently, the TASC clas-
sification of lesions has been modified to reflect in-
creased evidence for endovascular treatment of more
extensive femoropopliteal lesions, and indications for
endovascular repair have been expanded to more severe
TASC types. Currently, endovascular treatment is indi-
cated for femoropopliteal lesions ≤15 cm [1]. Few ran-
domized and controlled studies have been performed to
compare treatment strategies for femoropopliteal lesions.
Indeed, only three randomized studies have showed out-
comes in favor of primary stenting [2-4]. The Achilles’
heel of femoropopliteal stenting remains in-stent resten-
osis. In coronary arteries, drug eluting stents (DES),
combining a platform (a bare metal stent) and a drug
(cytostatic or cytotoxic drug) with or without a polymer,
have shown promising restenosis prevention results [5].
However, limus eluting stent for femoropopliteal lesions
failed to show consistent results, as for coronary arteries.
Indeed, sirolimus and everolimus drug eluting stents failed to
prove significant efficacy over bare metal stents for femoro-
popliteal lesions [6,7]. Conversely, in 2011, Dake et al.
showed that a paclitaxel-eluting stent was superior, in terms
of patency and reintervention, to balloon angioplasty with
provisional stenting to treat femoropopliteal lesions ≤14 cm
[8]. In a second arm of randomization, Dake et al. showed
that the application of paclitaxel eluting stents reduced
restenosis and reinterventions compared to bare metal
stent. Although this study demonstrated the superiority of
paclitaxel eluting stents over bare metal stents, the study
was not designed to compare bare metal stents to DES.
Consequently, no current studies have compared bare
stents to paclitaxel-eluting stents as a primary objective for
the treatment of the femoropopliteal segment.
Recently, Schulte et al. published the results of the
Misago® 2 trial [9]. The Misago® 2 trial was a prospective,
non-randomized multicenter study which evaluated the
safety and efficacy of a latest generation nitinol stent with
the first rapid-exchange (RX) monorail system (Misago®,
Terumo Corp., Tokyo, Japan). Seven hundred and forty-
four patients were enrolled in this study and followed up
for at least 1 year. During the inclusion period, 750 femor-
opopliteal lesions were treated with a mean lesion lengthof 63 mm. The authors showed a promising efficacy of the
Misago® RX nitinol stent system with a clinically driven
target lesion revascularization (TLR) rate of 89.9% at 1 year
compared with 90.5% for the paclitaxel eluting stent group
in the Zilver® PTX® randomized study [8]. Moreover,
primary patency was recorded in 574 (87.6%) patients
evaluated at 1 year post procedure. Although Misago® 2
was designed as a prospective registry without comparison
to other therapeutic options, this trial supports primary
stenting and the use of the Misago® RX nitinol stent as a
first-line treatment for femoropopliteal lesions.
The primary objective of the BATTLE trial is to dem-
onstrate the clinical superiority of primary stenting using
the Zilver® PTX® stent system versus a latest generation
bare nitinol stent (Misago® RX, Terumo Corp., Tokyo,
Japan) in the treatment of intermediate length femoro-
popliteal lesions in patients with symptomatic peripheral
arterial disease (Rutherford 2 to 5).Methods
The CONSORT Statement has been used to report the
trial’s design, conduct, analysis and interpretation, and to
assess the validity of its results [10,11]. The study has re-
ceived ethics approval (France: Comité de Protection des
Personnes Ouest IV; Switzerland: in process).Design of the study
The BATTLE clinical investigation is a prospective, ran-
domized (1:1), controlled, multicentric and international
trial in France and Switzerland. All randomized patients
will be included in the analysis (intent to treat principle).
The objective is to demonstrate the clinical superiority of
primary stenting using the Zilver® PTX® stent system versus
a latest generation bare nitinol stent (Misago® RX, Terumo
Corp., Tokyo, Japan) in the treatment of intermediate
length femoropopliteal lesions in patients with symptom-
atic peripheral arterial disease (Rutherford 2 to 5). The ex-
pected overall duration of the study is 48 months. The
enrollment period is 24 months and the patient follow-up
period is 24 months. The study design is summarized in
Figure 1.Study objectives and endpoints
Main objective
The main objective of the study is to demonstrate the
clinical superiority of primary stenting using the DES
(Zilver® PTX®) stent system versus bare metal self-
expandable stenting (Misago® RX) in the treatment of
intermediate length femoropopliteal lesions in patients
with symptomatic peripheral arterial disease (Rutherford
2 to 5).
Figure 1 Flow chart. Flow diagram of progress through the phases of a parallel-randomized trial of two groups.
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The study is powered based on the primary endpoint of
freedom from in-stent restenosis at 1 year, assessed by
duplex scan. Each examination comprises measurements
of the maximum peak systolic velocity (PSV) 2 cm prox-
imal to the culprit lesion (‘prestenotic’), within the lesion
(‘intrastenotic’), and up to 4 cm distal to the lesion
(‘poststenotic’). The ratio of the maximum intrastenotic
PSV and the maximum prestenotic PSV (peak velocity
ratio; PVR), represented by:
PVR ¼ PSVintrastenotic=PSVprestenotic
determines the degree of percent stenosis [12]. In-stent
restenosis is defined by restenosis >50% and by a peak
systolic velocity ratio (PSVR) >2.4 at the lesion site.
Secondary objectives
The secondary objectives are to assess the efficacy of
bare and paclitaxel drug eluting stents in terms of suc-
cess of the procedure (M1, M12, M24) and quality of life(M1, M12, M24) and to conduct an economic analysis
comparing the Zilver® PTX® drug-eluting stent to the
Misago® RX bare self-expanding stent.
Secondary endpoints
The following secondary endpoints will be examined:
 Technical success defined as achievement of a final
residual diameter stenosis of <30% on the
procedural completion angiogram
 Primary sustained clinical improvement at 1, 12 and
24 months post-procedure defined as a sustained
upward shift of 1 category of the Rutherford classifi-
cation for claudicants and by wound-healing and
resting pain resolution for patients in critical limb is-
chemia, without the need for repeated TLR in sur-
viving patients
 Secondary sustained clinical improvement at 1, 12
and 24 months post-procedure defined as primary
sustained clinical improvement including the need
for repeated TLR
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procedure defined as patency without any percutan-
eous or surgical intervention in the treated segment
or adjacent areas
 Major adverse clinical events (MACEs) at 1, 12 and
24 months post-procedure defined as MACEs in-
cluding all deaths or major amputation
 Limb salvage defined as freedom from major
ipsilateral amputations at 1, 12 and 24 months post-
procedure
 Death (all causes) at 1, 12 and 24 months post-
procedure
 Ankle brachial index at 1, 6, 12 and 24 months post-
procedure
 Target extremity revascularization (TER) at 1, 12
and 24 months post-procedure. TER is defined as
any percutaneous intervention or surgical bypass of
any segment of the target extremity. The target ex-
tremity is defined as the ipsilateral limb arteries
proximal and distal to the target lesion, including
upstream and downstream branches and excluding
the target lesion itself
 Target lesion revascularization at 1, 12 and
24 months post-procedure. TLR expresses the fre-
quency of the need for repeated procedures (endo-
vascular or surgical) due to a problem arising from
the stent (1 cm proximally and distally to include
edge phenomena) in surviving patients with pre-
served limb
 Stent fracture at 1, 12 and 24 months. Stent
fractures, assessed by biplane X-rays. Biplane X-rays,
should be performed with two different projections
separated by at least 45°, with the patient in a prone
position. If this strategy does not cover the entire
stented segment, additional views should be ob-
tained. High-resolution images should be obtained
either in a diagnostic X-ray room or a fixed unit
angiography suite and saved to DICOM files
 Quality of life at 1, 12 and 24 months assessed
according the EuroQol-5D-3 L (EQ-5D-3 L)
questionnaire
 Economic analysis endpoints: incremental
cost-effectiveness ratio based on quality of life for
cost-utility analysis and on freedom from in-stent
restenosis for cost-effectiveness analysis will be
performed to conduct an economic analysis
Population
Recruitment
All patients presenting with chronic symptoms of lower
extremity peripheral arterial disease will be screened for
participation in the clinical investigation. A member of
the research team previously trained in the study proto-
col should screen patients admitted for a percutaneousfemoropopliteal artery revascularization procedure for
study eligibility. Patients who fail to satisfy inclusion and
exclusion criteria will not be randomized in this study.
Patients meeting the general inclusion and exclusion cri-
teria will be asked to sign, date and time an informed
consent for Switzerland. In France, an informed consent
will not be required and information will be given to the
patient since the BATTLE trial is considered as a current
health care study. After inclusion, a randomization num-
ber and treatment arm must be assigned by an inter-
active web-based randomization service.
Inclusion criteria
 Patient ≥18 years
 Patient has a history of symptomatic peripheral
arterial disease (Rutherford classification: 2 to 5)
 Lesion is eligible for treatment with a maximum of
two stents per lesion (treatment of both legs is not
permitted)
 De novo atherosclerotic lesions (stenosis and/or
occlusion) of the superficial femoral artery (SFA),
the proximal popliteal artery (P1), or both. The
treatment area in the SFA and popliteal artery
extended from 1 cm below the origin of the
profunda femoral artery to 3 cm above the proximal
margin of the intercondylar fossa of the femur
 Resting ankle brachial index (ABI) <0.9
 Patient is affiliated to the Social Security or
equivalent system
 Patient has been informed of the nature of the
study, agrees to its provisions prior to any study-
related procedure
 Patient agrees to undergo all protocol-required
follow-up examinations and requirements at the in-
vestigational site
 Reference vessel diameter 4 to 7 mm determined by
computed tomography (CT) scan (reference vessel
diameter obtained from averaging 5-mm segments
proximal and distal to the lesions)
 Target lesion has a preprocedure percent diameter
stenosis of ≥50% diameter stenosis
 Target lesion has a length ≥2 cm and ≤14 cm
 At least 1 patent runoff vessel (<50% diameter
stenosis throughout its course). The inflow artery





 No atheromatous disease
 Untreated >50% diameter stenosis of the inflow tract
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 Patient has received, or is on the waiting list for a
major organ transplant
 Patient has a history of coagulopathy or will refuse
blood transfusions
 Patient is receiving or scheduled to receive
anticancer therapy for malignancy within 1 year
prior to or after the procedure
 Severe concomitant disease with life expectation
<1 year
 Known allergy to paclitaxel
 Contraindication to aspirin or clopidogrel and
ticlopidin (the patient must be able to receive dual
antiplatelet treatment for 2 months after the
procedure)
 Patient has an infected wound or osteomyelitis on
the ipsilateral extremity or foot
 Patient has had prior major amputation to the
ipsilateral (target) extremity
 Patient is not able to give informed consent (for the
Swiss center only)
 Patient is currently participating in an investigational
drug or device study that has not completed the
primary endpoint or that clinically interferes with
the current study endpoints (Note: trials requiring
extended follow-up for products that were investiga-
tional, but have become commercially available since
then, are not considered investigational trials)
 Patient has previously had, or requires, bypass
surgery, endarterectomy or other vascular surgery
on any vessel of the ipsilateral extremity
 In the investigator’s opinion, the patient has co-
morbid condition(s) that could limit the patient’s
ability to participate in the study, compliance with
follow-up requirements or impact the scientific in-
tegrity of the study
 Target lesion lies within or adjacent to an aneurysm
 Patient with an allergy to contrast agent
 Patient with a severe allergy to metal
Randomization
Randomization will be conducted via Capture System
software by connecting to the website: https://www.dirc-
hugo-online.org/csonline/. The connection will be made
via a login, password and study name (BATTLE), given
by a data manager from the Nantes University Hospital
Research Department. The following information should
be provided: the first letter of the first name, the first let-
ter of the surname, the birth date, the compliance with
inclusion criteria and exclusion criteria (yes/no).
The number and the randomization arm will be
assigned automatically at the time of randomization.
A statistician, from the Nantes University Hospital
Research Department, will prepare the randomizationlist. An explanatory guide of randomization will be
available online via Capture System.
Interventions
Description of the investigational devices
The Misago® RX is a peripheral bare metal stent (Misago®
RX, Terumo Corp., Tokyo, Japan) indicated to treat iliac
and femoropopliteal arteries. The Misago® RX is a flexible
self-expanding nitinol stent that is delivered via an RX
monorail delivery catheter.
The Zilver® PTX® (Cook Medical, Bloomington, IN,
USA) is a peripheral drug eluting stent with a polymer-
free paclitaxel coating indicated to treat the above-the-
knee femoropopliteal arteries. The anti-proliferative drug
is paclitaxel, a cytotoxic drug. The Zilver® PTX® is a flex-
ible self-expanding nitinol stent that is delivered via an
over-the-wire system.
Procedure
Local anesthesia with conscious sedation is recom-
mended unless general anesthesia is required. Access to
the culprit SFA lesion is achieved at the investigator’s
discretion either by way of a retrograde approach from
the contralateral femoral artery with the use of a dedi-
cated 6 F sheath. An intravenous bolus of 50 IU/kg hep-
arin is administered. The same antiplatelet regimen is
recommended for all patients: clopidogrel starting at
least 24 hours before the intervention or a procedural
loading dose of 300 mg orally. Stenotic lesions are
crossed in an intraluminal fashion and occlusions are
recanalized at the physician’s discretion (intraluminal or
subintimal recanalization should be recorded in the elec-
tronic case report form; eCRF). A guidewire is posi-
tioned through the lesion. Primary stenting is preferably
performed using the assigned stent. The stent dimen-
sions are determined according the baseline morpho-
logical analysis. The stent diameter is selected such that
4 to 5.5 mm vessels should be treated with a 6 mm stent
and that 5.6 to 7 mm vessels should be treated with a
7 mm stent (CT scan estimate); and the length exceeds
the lesion length by 2 to 5 mm proximal and distal. Refer-
ence vessel diameter is determined by CT scan (reference
vessel diameter obtained from averaging 5-mm segments
proximal and distal to the lesions). The largest diameter
should be used. Stents are placed at least 1 cm below the
origin of the profunda femoral artery to 3 cm above the
proximal margin of the intercondylar fossa of the femur.
A maximum of 10 mm overlap is allowed in cases requir-
ing 2 stents. Preinflation and postinflation are performed
at the physician’s discretion. In the event of preinflation or
postinflation, the balloon dimension is chosen such that 4
to 5.5 mm vessels should be treated with a 5 mm balloon
diameter and that 5.6 to 7 mm vessels should be treated
with a 6 mm balloon diameter (CT scan estimate) and so
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Residual diameter stenosis <30% is required for technical
success. The technical result of the procedure is assessed
by digital subtraction angiography. All associated inflow
or outflow lesions suspected to be involved in the disease
are treated during the same procedure. Drug eluting
devices are forbidden to treat inflow and/or outflow
lesions. Groin closure could be accomplished via manual
compression or using a vascular closure device. Each
enrolling investigator must review the most recently
updated instructions for use and assess the contraindica-
tions, warnings, potential adverse events and precaution
sections for treating potential patients.
Follow-up (Table 1)
Follow-up schedule
All patients randomized into the clinical investigation
will have clinical follow-up at:














Rutherford classification ✓ ✓
Quality of life questionnaire ✓ ✓
Preoperative angiography,





Peripheral angiogram with runoff ✓1
Ankle brachial index (ABI)/Toe
brachial index if ABI >1.3 or not
able to be reliably measured
✓ ✓
Duplex ultrasound ✓ ✓ (within the first
4 weeks)
Stent radiography ✓
Per protocol medications2 ✓ ✓





1Peripheral angiogram (procedural/post-procedure) for all patients.
2Aspirin ≥75 mg daily must be given for a minimum of 2 months, and clopidogrel 7
(2 years) post-procedure.
CT, computed tomography.
MRA, magnetic resonance angiogram. 12 months post-procedure ±1 month
 24 months post-procedure ±1 month
All patients will undergo quality of life assessment at:
 4 weeks post-procedure ±2 weeks
 12 months post-procedure ±1 month
 24 months post-procedure ±1 month
All patients will undergo a duplex scan at:
 Within the first 4 weeks
 6 months post-procedure ±1 month
 12 months post-procedure ±1 month
 24 months post-procedure ±1 month
All patients will undergo stent radiography at:
 4 weeks post-enrolment ±2 weeks
 12 months post-procedure ±1 month















✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
✓ ✓ ✓ ✓
5 mg daily to be taken throughout the length of the study
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All patients randomized into the study will be maintained
on 2 antiplatelet agents combining aspirin (75 mg) and a
thienopyridine. Aspirin (75 mg) will be given daily for a
minimum of 2 months following the procedure. A thieno-
pyridine (for example, 75 mg of clopidogrel) must be
taken throughout the length of the study (2 years). If a pa-
tient develops sensitivity to clopidogrel, they may be
switched to ticlopidine hydrochloride at a dose according
to standard hospital practice. When patients are receiving
oral anti-coagulant treatment, aspirin is the only antiplate-
let agent added. These medications can be halted for med-
ical necessity if required. However, they must be resumed
as soon as possible per physician discretion. The start of
antiplatelet medications and termination of will be docu-
mented in the eCRF. The medication history should be
updated as needed to include modifications to the con-
comitant medications and protocol-required medications.
Duplex scan follow-up
Patients will have a follow-up by duplex scan within the
first 4 weeks, 6 months (±1 month), 12 months (±1 month)
and 24 months (±1 month). Doppler ultrasound examina-
tions will be registered on a CD or DVD. Information will
be collected on standardized forms filled during duplex
scan examination including Rutherford classification,
ABI, PSVR, run-off, per-protocol medications and ad-
verse events. The forms and the CD (or DVD) will be
returned to the investigator. High-resolution images
should be saved. Duplex scan examinations will be
downloaded in the eCRF to be analyzed online by an
independent core laboratory.
Stent radiography follow-up
To standardize evaluation of stent fractures, biplane X-
rays of the femoropopliteal arterial segment (including
the hip and the knee) should be performed to cover the
entire stented segment. An exposure <80kVp using a
magnification of 1.5 image intensifier/receptor magnifi-
cation is recommended ato obtain the greatest coverage
of the stent. If this strategy is insufficient, additional
views should be obtained. X-rays should be performed
with 2 different projections separated by at least 45°,
with the patient in a prone position. High-resolution im-
ages should be saved to DICOM files. Stent radiography
will be downloaded in the eCRF to be analyzed online by
an independent core laboratory.
Type of comparison
The study objective is to determine whether DES (Zilver®
PTX®) will be superior to a latest generation bare nitinol
stent (Misago® RX, Terumo Corp., Tokyo, Japan) in the
treatment of intermediate length femoropopliteal lesionsin patients with symptomatic peripheral arterial disease
(Rutherford 2 to 5).
Type of analysis
According to the intent to treat principle, all randomized
patients will be included in this analysis and a censoring
mechanism will be applied to those patients without an
event over 1 year of study follow-up. The time-to-first
event (in-stent restenosis) will be calculated as the first re-
stenosis date. Patients without an in-stent restenosis at the
end of 1 year of study follow-up will have their efficacy
measure censored at M12. Patients who withdraw from
the study before completing 1 year of study follow-up, and
have not experienced an event, will have their time-to-
event measure censored on their withdrawal date. Patients
without an event and who are lost to follow-up will be
censored at the day of last contact. This concept will be
applied to both Zilver® PTX® and Misago® patients. Every
effort will be made to have zero patients lost to follow-up
and to encourage the investigator to keep patients under
study observation. In both arm groups, for patients who
died before the final follow-up examination or for patients
lost to follow-up, the status of the last follow-up examin-
ation was recorded.
Power calculation
The null (H0) and alternative (HA) hypotheses for the
primary endpoint of freedom from in-stent restenosis at
1 year are:
H0: freedom from in-stent restenosis at 1 year (Zilver®
PTX®) ≠ freedom from in-stent restenosis at 1 year
(Misago® RX)
HA: freedom from in-stent restenosis at 1 year (Zilver®
PTX®) = freedom from in-stent restenosis at 1 year
(Misago® RX)
The sample size calculation for the primary endpoint
is based on the following assumptions: two-sided super-
iority test, α =0.05, randomization ratio is 1 (Zilver®
PTX®): 1 (Misago® RX arm), and a power of 80%. The
true freedom from in-stent restenosis rate is assumed
to be 86.2% for Zilver® PTX® arm [8]. The BATTLE trial
is designed to assess primary stenting in the treatment
of intermediate length femoropopliteal lesions. Conse-
quently, we have used Vienna, Astron and Durability
results in which the mean length of the treated lesions
is longer (101, 82 and 96.4 mm respectively). Indeed, in
the Misago trial the 750 femoropopliteal lesions were
treated with a mean lesion length of 63 mm. Therefore,
the average of the true freedom from in-stent restenosis
rate in the bare metal stent group was 66.9% (Δ for
superiority = 0.862 to 0.669 = 19.3%) [2-4]. S-PLUS
software (TIBCO, CA, USA) will be used to determine
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between two proportions. Based on the above assump-
tions, a total of 170 patients (85 patients for each arm)
will provide approximately 80% power. Assuming an
approximately 10% dropout rate at 1 year, 186 patients
will be randomized (93 patients for each arm). The
variance needed to construct the test statistic depends
on the parameters being tested. It seems reasonable to
use all of the data available to estimate the variances,
and this is exactly what S-PLUS does. A weighted
average of the two estimates for the proportions will be
used to estimate the variance under H0.
Statistical analysis
The primary statistical methodology for this study will be
based on the Kaplan-Meier estimates of the survivor func-
tion, life table estimates of the survivor and hazard ratio
(95% CI) computed using the Cox proportional hazards
model. A log rank test will be used to assess the statistical
significance of observed arm differences in the time-to-
event distributions between the Zilver® PTX® and Misago®
groups. The log rank test statistics, P-values, Kaplan-
Meier estimates, and life table estimates will be obtained
from the SAS® V9.3 procedure LIFETEST (Cary, NC,
USA). The Cox proportional hazards model will be used
to obtain an estimate of the hazard ratio for the Zilver®
PTX® group to the Misago® group. A 95% confidence
interval will be computed for the hazard ratio. In addition,
the Cox proportional hazards model with group and
potential baseline variables will be used to estimate the
adjusted hazard ratio of Zilver® PTX® group to the Misago®
RX group. Analysis of the primary endpoint will be on a
per-patient basis. Analysis based on the per treatment
evaluable population will also be performed.
Trial management and quality assurance
A clinical research assistant (CRA) representing the spon-
sor will schedule monitoring visits regularly. During these
visits, the CRA will review study plan compliance, adher-
ence to the protocol, and data quality. The CRA will com-
pare eCRFs and ensure that the study is being conducted
in compliance with pertinent regulatory requirements.
The investigator will provide the CRA with direct access
to eCRFs and to the subject’s records (for example,
medical records, office charts, hospital charts, and study-
related charts) for source data verification, as well as any
other study documents.
Discussion
The aim of the BATTLE trial is to compare the pacli-
taxel eluting stent (Zilver® PTX®) with a latest generation
bare self-expendable nitinol stent (Misago® RX, Terumo
Corp., Tokyo, Japan) in the treatment of intermediate
length femoropopliteal lesions (≤14 cm). We decided toevaluate only intermediate length femoropopliteal le-
sions for several reasons. Firstly, most trials have investi-
gated femoropopliteal lesions ≤15 cm length with lesion
length ranged from 45 to 101 mm and consequently,
according to the TASC, endovascular treatment for
femoropopliteal lesions is indicated for TASC A and B
lesions [1]. Secondly, Zilver® PTX® DES is indicated for
lesions ≤14 cm according the inclusion criteria and the
results of the Zilver® PTX® trial [8]. Also, the use of DES
for longer lesions has not been sufficiently evaluated
and, moreover, the maximal length of Zilver® PTX® is
12 cm. Finally, we decided to exclude short lesions
(<2 cm) since in the FAST trial, the primary stenting of
short femoropopliteal lesions did not show better results
than angioplasty.
Our primary endpoint is freedom from in-stent
restenosis at 1 year, as assessed by duplex scan. In-
stent restenosis is defined by restenosis >50% and by a
PVR >2.4 at the lesion site. Duplex scan is a standard
clinical technique used to evaluated in-stent stenosis.
Currently, duplex scan is the routine modality for im-
aging follow-up of lower limbs since it is non-invasive,
low-cost and the diagnosis value of duplex scan seems
comparable to digital subtraction arteriogram [13,14].
Only de novo atheromatous femoropopliteal lesions
will be included and, consequently, we have excluded in-
stent restenosis. Indeed, the treatment of in-stent resten-
osis seems different since its composition associates not
only an atheromatous plaque, but also a proliferation
and migration of smooth muscle cells, an inflammatory
process and a matrix deposition and accumulation.
Regarding the antiplatelet regimen, there is no evidence-
based medicine in the setting of peripheral arterial disease
stenting. Consequently, we have chosen the same protocol
as the Zilver® PTX® trial that combines aspirin and clopi-
dogrel for at least 60 days after the procedure and lifelong
aspirin therapy [8].
The sample size calculation for the primary endpoint is
based on the assumptions of 13.8% and 33.1% of in-stent
restenosis in the Zilver® PTX® group and the bare metal
stent group respectively. The rate of in-stent restenosis for
the DES group was given by the Zilver® PTX® study,
whereas the rate of in-stent restenosis for the bare metal
stent group was given by the mean of in-stent restenosis
of three different studies: Vienna, Astron and Durability
[2-4]. In these trials, the mean lesion length and in-stent
restenosis rates were 101, 82, 96.4 mm and 37%, 34.4%
and 27.8% respectively. Considering these studies, the
average in-stent restenosis rate was 33.1%. We considered
that these studies were more relevant due the intermedi-
ate length of the treated lesions.
One limitation could almost already be addressed: the
BATTLE trial is not a blinded study. Indeed, some differ-
ences exist according to the device. For example, the
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http://www.trialsjournal.com/content/15/1/423Zilver® PTX® stent is delivered via an over-the-wire-de-
livered catheter, whereas the Misago® RX is delivered via
a RX-delivered catheter. Moreover, Zilver® PTX® stent
deployment is controlled by retraction of the handle
while holding the metal cannula stationary. For the
Misago RX®, a small ergonomic handle controls the
release of the stent using a single hand.
Trial status
Recruitment began in February 2014 and is expected to
take 2 years.
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